objective study efficacy newly designed treatment strategy esthesioneuroblastoma neuroendocrine carcinoma paranasal sinuses design setting nonrandomized prospective study case series tertiary referral center patients consecutive patients newly diagnosed esthesioneuroblastoma neuroendocrine carcinoma paranasal sinuses june NUMBER october NUMBER underwent treatment protocol interventions histological diagnosis detailed imaging NUMBER cycles cisplatin etoposide chemotherapy instituted chemotherapy responders treated combined photon stereotaxic fractionated proton radiation therapy totaling approximately NUMBER gy primary site poor responders treated surgical resection followed postoperative radiation cases therapy concluded NUMBER additional cycles cisplatin etoposide chemotherapy main outcomes measures response therapy survival survival complications therapy examined results patients median dulguerov t stage t3 range t2 t4 completed treatment protocol mean diagnosis NUMBER months NUMBER patients exhibited dramatic response therapy remission tumor resection required patient failed respond induction chemotherapy received surgical therapy followed postoperative radiotherapy recurrences mean interval NUMBER months complications limited generally transient conclusions use combined cisplatin etoposide chemotherapy proton radiation demonstrated initial success treatment tumors dramatic response chemotherapy possible bulky unresectable disease protocol acceptable complication rate conveys morbidity craniofacial resection conventional radiotherapy required determine success rate therapeutic protocol disease free follow disease free follow long term